Results 41 to 50 of about 289,586 (356)
We describe the current Good Manufacturing Practice (cGMP) production and subsequent characterization of eOD-GT8 60mer, a glycosylated self-assembling nanoparticle HIV-1 vaccine candidate and germline targeting priming immunogen.
Vaneet K. Sharma+11 more
doaj +1 more source
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
COVID-19 pandemic is a global public health emergency. Despite extensive research, there are still few effective treatment options available today. Neutralizing-antibody-based treatments offer a broad range of applications, including the prevention and ...
Mingtao Liu+11 more
doaj +1 more source
Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco [PDF]
The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV-1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most ...
EMEA+4 more
core +1 more source
The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2
Summary: Animal reservoirs of sarbecoviruses represent a significant risk of emergent pandemics, as evidenced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
Joel D. Allen+8 more
doaj
Dengue virus neutralization in cells expressing Fc gamma receptors. [PDF]
Activating Fc gamma receptors (FcγRs) in hematopoietic cells serve to remove antibody-opsonized antigens, including dengue virus (DENV), from systemic circulation. While neutralizing antibody concentrations provide humoral immunity, cross-reactive or sub-
Tanu Chawla+6 more
doaj +1 more source
NEUTRALIZING ANTIBODIES IN ABORTIVE POLIOMYELITIS [PDF]
The neutralizing antibody content for poliomyelitis virus has been tested with both a human and a passage strain of the virus in serial samples of sera from five mild cases of abortive poliomyelitis, and an increase in this antibody content has been demonstrated in convalescent samples obtained within 4 weeks of the acute illness.
John R. Paul, James D. Trask
openaire +3 more sources
Exposure to common noxious agents (1), including allergens, pollutants, and micro‐nanoplastics, can cause epithelial barrier damage (2) in our body's protective linings. This may trigger an immune response to our microbiome (3). The epithelial barrier theory explains how this process can lead to chronic noncommunicable diseases (4) affecting organs ...
Can Zeyneloglu+17 more
wiley +1 more source
Soluble HIV-1 envelope glycoprotein (Env) trimers are under active investigation as vaccine candidates in relevant pre-clinical models. Like SOSIPs, the cleavage-independent native flexibly linked (NFL) trimers are faithful mimics of the Env spike. Here,
Lifei Yang+13 more
doaj +1 more source
Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology. [PDF]
The lack of standardization of the currently used commercial anti-rubella IgG antibody assays leads to frequent misinterpretation of results for samples with low/equivocal antibody concentration.
Iana H Haralambieva+6 more
doaj +1 more source
Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state [PDF]
Human respiratory syncytial virus (RSV) is the main cause of lower respiratory tract infections in young children. The RSV fusion protein (F) is highly conserved and is the only viral membrane protein that is essential for infection.
Chen, Man+13 more
core +2 more sources